November 6, 2019 Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
Read More
November 6, 2019 Ryvu Therapeutics Reports Third Quarter 2019 Financial Results
Read More
November 5, 2019 Ryvu Therapeutics to Present at BIO-Europe 2019
Read More
October 14, 2019 Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board
Read More
October 3, 2019 Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Read More
October 1, 2019 Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Read More
September 19, 2019 Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Read More
September 6, 2019 Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Read More
September 3, 2019 Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed
Read More
July 25, 2019 Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Read More
July 24, 2019 Selvita to Present at Upcoming Conferences in September
Read More
May 16, 2019 Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress
Read More
May 13, 2019 Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Read More
April 17, 2019 Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting
Read More
April 4, 2019 Selvita to present at the 2019 HCW Global Life Sciences Conference in London
Read More
March 28, 2019 Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies
Read More
March 26, 2019 Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Read More
March 4, 2019 Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting
Read More
January 2, 2019 Selvita to Present at Biotech Showcase 2019 in San Francisco
Read More
August 8, 2014 New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read More
